COVID-19 in Patients With Chronic Liver Diseases

CompletedOBSERVATIONAL
Enrollment

1,025

Participants

Timeline

Start Date

March 6, 2020

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions
COVID-19Chronic Liver Disease
Interventions
OTHER

Prospective Chart Review

Collected data will include demographic features, clinical characteristics, clinical outcome, medication use, COVID-19-related complications in patients with chronic liver disease.

Trial Locations (23)

10029

Mount Sinai School of Medicine, New York

10065

Weill Cornell Medicine, New York

15213

University of Pittsburgh Medical Center, Pittsburgh

19104

University of Pennsylvania, Philadelphia

20057

Georgetown University, Washington D.C.

20422

VA Medical Center, Washington D.C.

27710

Duke University, Durham

33136

University of Miami, Miami

44106

University Hospitals Cleveland Medical Center, Cleveland

48109

University of Michigan, Ann Arbor

55415

Hennepin County Medical Center (HCMC), Minneapolis

55455

University of Minnesota, Minneapolis

60612

Rush University Medical Center, Chicago

66160

The University of Kansas Medical Center, Kansas City

70816

Oschner Medical Center, Baton Rouge

85004

University of Arizona,, Phoenix

85259

Mayo Clinic, Scottsdale

90007

University of Southern California, Los Angeles

93701

UCSF Fresno, Fresno

94305

Stanford University, Stanford

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Stanford University

OTHER

NCT04439084 - COVID-19 in Patients With Chronic Liver Diseases | Biotech Hunter | Biotech Hunter